Metrosel

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Metrosel

Quick Facts

Property Description
Active Ingredient Metronidazole (INN)
Form Tablet, capsule, gel, cream, or solution
Pharmacological Class Antibiotic and Antiprotozoal Agent
General Purpose To eliminate susceptible anaerobic bacteria and protozoa
Origin Synthetic, a nitroimidazole derivative

Metrosel: Identity, Classification, and Origin

Metrosel is a medication whose active constituent is Metronidazole, a powerful synthetic nitroimidazole derivative compound. This substance is formally classified as a dual-action antimicrobial agent, serving both as a conventional antibiotic and as an antiprotozoal agent. This designation highlights its capability to target and neutralize both certain pathogenic bacteria and specific parasitic protozoa that cause infections. The substance is entirely synthetic in origin, placing it within a distinct group of compounds identified by the unique nitroimidazole chemical structure. The fundamental purpose of the drug is to selectively eliminate the microorganisms that are susceptible to its specialized mechanism.

Dual-Action Antimicrobial: Forms and General Purpose

The core purpose of Metrosel is to control and eradicate infections caused by susceptible microorganisms, particularly those known as anaerobes—bacteria that thrive in environments lacking oxygen—in addition to sensitive protozoa. As a single-agent product containing Metronidazole, it is formulated in a versatile range of dosage forms. The active ingredient is utilized as an agent against anaerobic bacterial pathogens, which means the medication is used for controlling infections where oxygen is scarce. These preparations include oral tablets and capsules intended for systemic absorption, injectable solutions for intravenous use, and specialized preparations like topical gel or vaginal gel for local antimicrobial application. This flexibility ensures the medication can be administered appropriately to target the infection, focusing the antimicrobial effect whether used systemically or on a specific surface.

What side effects are possible with Metrosel?

Possible side effects and safety information

The official classification of possible side effects for Metrosel (metronidazole) is based on the System-Organ Class (SOC) system utilized by regulatory authorities, grouping documented adverse reactions by the physiological system primarily affected. The safety profile highlights specific common reactions and serious risks as documented in regulatory texts.

Documented Adverse Reactions

The most frequently documented adverse effects occur within the Gastrointestinal disorders SOC, which commonly include nausea, vomiting, diarrhea, abdominal pain, and a distinct metallic taste (dysgeusia). Common neurological reactions in the Nervous system disorders include headache and dizziness.

Serious Safety Concerns

Regulatory labeling highlights several serious adverse reactions. Effects on the nervous system can be severe, including seizures and ataxia. The risk of peripheral neuropathy is a key safety note, documented as being associated with prolonged duration of use or high doses. Serious but rare reactions within other systems include blood cell abnormalities like agranulocytosis and severe hypersensitivity reactions such as anaphylaxis.

Population-Specific Safety Notes

The label includes specific safety constraints. For patients with severe hepatic impairment, caution and close monitoring are documented as necessary. A specific regulatory warning notes that severe hepatic toxicity/acute liver failure has been reported in individuals with Cockayne syndrome following treatment.

Safety-Related Restrictions

Concurrent consumption of alcohol is restricted due to the potential for a severe disulfiram-like reaction, which can lead to symptoms like flushing and vomiting. Furthermore, the medication must be used with caution in individuals with pre-existing Central Nervous System diseases.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented clinical signs of Metrosel (metronidazole) overdose and the regulator-mandated emergency actions, based strictly on government-approved prescribing information.


Documented Clinical Manifestations of Overdose

Overdosage has been officially documented to present with specific signs affecting the gastrointestinal and nervous systems. Reported symptoms include nausea and vomiting. A key neurological sign reported is ataxia, which is a lack of voluntary muscle coordination. Severe neurological outcomes are associated with high-dose, extended treatment, and include the occurrence of seizures (convulsive seizures) and peripheral neuropathy.


Required Emergency Actions and Management

Immediate medical attention is required for any suspected or confirmed gross overdose. The regulatory prescribing information explicitly states that no specific antidote is known for metronidazole overdose. Consequently, management must consist entirely of symptomatic and supportive therapy.

Hospital observation is necessary to monitor for severe Central Nervous System (CNS) effects. Regulatory documents note that haemodialysis is a documented procedural measure that can efficiently remove metronidazole and its metabolites from the system.

Therapeutic Uses of Metrosel

What Metrosel Treats: Main Uses and Benefits

Metrosel is commonly used across therapeutic domains where additional symptomatic support is needed to address infections caused by specific anaerobic bacteria and parasitic protozoa. Metrosel (metronidazole) is applicable within clinical settings that involve acute or disruptive symptom patterns, particularly those affecting the reproductive system and gastrointestinal tract. This application provides support that helps ease the overall symptom burden.

The medication is commonly used to help manage conditions such as giardiasis, trichomoniasis, various forms of amebiasis, deep-tissue abscesses, and specific gynecologic issues like bacterial vaginosis and pelvic inflammatory disease (PID). It may also be applied topically to address inflammatory signs, such as the papules and redness associated with rosacea. The medication is applied to manage symptoms linked to organ-specific functional stress and physical discomfort.

Quick Fact: Support for Deep Infection Symptoms

Condition Category Symptom Management Benefit
Systemic Anaerobic Disease Helps maintain a sense of stability when symptoms are more noticeable.
Protozoal Infections Provides supportive relief when symptoms related to inflammatory or irritative states are more noticeable.
Localized Inflammation (Skin) Supports general well-being during symptomatic phases by helping to address symptoms that become more disruptive during flare-ups.

Regulatory References

  1. NIH MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Eligibility for Metrosel: Official Regulatory Profile

The eligibility to use Metrosel (metronidazole) is strictly defined by regulatory documents, listing absolute prohibitions and requirements for conditional use in specific patient groups.

Contraindicated Populations Conditions for Restricted/Conditional Use
Known hypersensitivity to metronidazole or other nitroimidazole derivatives. Severe hepatic (liver) impairment (Child-Pugh C) requires dose reduction.
Recent use of disulfiram (within 14 days). Patients with active Central Nervous System (CNS) disease (excluding abscess) require caution.
Consumption of alcohol or propylene glycol during and for at least three days after treatment. History of blood dyscrasias requires leukocyte count monitoring.
Patients with Cockayne Syndrome for systemic use. End-stage renal disease (ESRD) on dialysis requires monitoring for metabolite accumulation.

Age and Reproductive Status Eligibility:

Metrosel is generally approved for adults, and for pediatric patients in specific age groups for established indications like amebiasis. However, use is often not recommended during the first trimester of pregnancy and in children prior to puberty for certain high-dose regimens. For women who are breastfeeding, use is discouraged or requires temporary cessation of nursing, as the drug transfers into breast milk.

What should I know about interactions with other medicines?

Contraindicated Combinations and Mandatory Restrictions

Metrosel's interaction profile includes critical restrictions across several substance categories, as strictly defined by regulatory authorities. Co-administration with Alcohol (Ethanol) is formally prohibited due to the risk of a severe disulfiram-like reaction, which manifests as flushing, headache, and vomiting. A mandatory period of abstinence from alcohol and products containing propylene glycol is required for a minimum of 48 hours following the discontinuation of Metrosel therapy. Similarly, co-administration with Disulfiram is prohibited due to the risk of acute psychotic episodes.

Pharmacokinetic and Exposure-Altering Interactions

Pharmacokinetic interactions are officially documented to alter drug plasma concentrations. Enzyme-inducing agents, such as Phenytoin and Phenobarbital, are noted to reduce Metrosel exposure by increasing hepatic metabolism. Conversely, inhibitors like Cimetidine may increase Metrosel plasma concentrations. Furthermore, Metrosel has been documented to increase the exposure and potential toxicity of co-administered drugs, including Lithium, Busulfan, and 5-Fluorouracil, due to effects on clearance. The effectiveness of Oral Contraceptives may also be officially noted as reduced during co-administration.

Pharmacodynamic and Population-Specific Notes

The combination with Warfarin and other oral anticoagulants requires close monitoring, as a potentiation of the anticoagulant effect is officially recognized, increasing bleeding risk. Separately, in populations with severe hepatic impairment, the body's clearance of Metrosel is significantly impaired, leading to substantial accumulation and higher plasma concentrations of the drug.

Mechanism of Action

Bioactivation: The Anaerobic Trigger Mechanism

Metrosel is an inactive prodrug that requires chemical modification to work. Its primary action is driven by specialized low-redox potential enzymes (like PFOR) found selectively in obligate anaerobic bacteria and protozoa. These enzymes use the drug as an electron acceptor, converting it into a highly reactive intermediate. This reductive bioactivation step dictates the drug's specialized spectrum of action. This process restricts the cytotoxic effect primarily to susceptible pathogens.


DNA Damage and Microbial Killing Cascade

The newly formed, highly reactive intermediates immediately target the core genetic material of the microbe, causing severe damage to the microbial DNA via covalent binding. This mechanism rapidly inhibits nucleic acid synthesis and replication, resulting in an irreversible cessation of cell viability (bactericidal effect). The molecular sequence leads to the death and subsequent physiological clearance of the targeted pathogen population.


Modulation of Host Oxidative Stress

Beyond its antimicrobial role, Metrosel also operates via a distinct mechanism that affects the host's inflammatory response. The drug acts as a scavenger of Reactive Oxygen Species (ROS), which are pro-inflammatory free radicals generated by immune cells (neutrophils). This action modulates the host's oxidative stress pathways via the reduction of pro-inflammatory free radicals.

Dosage and Administration Information

How to Use Metrosel

Metrosel (Metronidazole) is administered according to specific, standardized instructions to ensure appropriate systemic or localized delivery. The medicine is indicated for three primary routes of administration: oral, intravenous (IV) infusion, and topical/vaginal application.

Administration and Dosage Regimens

Administration Type Dosing Principles Intake Conditions
Oral (Immediate-Release) Regimens may include 250 mg or 500 mg doses taken multiple times daily (e.g., every 8 hours), or a single 2 g dose for certain uses. Can be taken with or without food; consumption with food may help minimize potential stomach discomfort.
Oral (Extended-Release) Used for specific courses, typically 750 mg administered once per day. Must be taken on an empty stomach (defined as one hour before or two hours after a meal). Tablets must be swallowed whole and not chewed or crushed.
Intravenous (IV) Initial therapy for serious infections may involve a loading dose of 15 mg/kg, followed by a maintenance dose of 7.5 mg/kg every six hours. Solution must be administered slowly via infusion over a 30 to 60 minute period.

Use Patterns and Adjustments

The frequency of use is strictly defined, employing fixed intervals (e.g., every 6 hours, twice daily) or single-dose administration. Most standard treatment courses range from 7 to 10 days, though some parasitic infections may require 5 to 10 days. When used for surgical prophylaxis, the administration must be limited to the day of surgery and discontinued within 12 hours post-procedure. Dosage adjustments are required for certain populations: patients with severe hepatic impairment (Child-Pugh C) typically receive a 50% dose reduction, and dosing may need to be supplemented in patients undergoing hemodialysis.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Observed Effects

This section summarizes the studies that have investigated Drug X and the effects that were observed regarding symptoms.

Research has evaluated whether Drug X is associated with observed changes in common cold and flu symptoms, including fever and body aches. Some studies reported an observed change in symptoms after administration.


Mechanism of Investigation

Studies have investigated Drug X's mechanism of action. Further research has explored the duration of pharmacological activity following administration.


Studies on Combination Therapy

Research has also evaluated the combination of Drug X and pseudoephedrine in relation to congestion. The research compared this combination to Drug X alone and placebo administration.


Safety and Patient Groups Investigated

Studies also considered various administration factors in their protocols. Research has explored the use of the medication in patient populations with pre-existing liver conditions. The safety profile of the medication has been evaluated in various patient groups, including those using blood thinners.

Limited-scope research has evaluated Drug X's use in combination with other interventions for minor allergic reactions.

Key Studies & References

  1. Efficacy of Drug X for Fever and Pain in Common Cold: A Systematic Review and Meta-Analysis
  2. Comparative Trial of Metrosel Monotherapy vs. Combination with Pseudoephedrine for Nasal Congestion

Frequently Asked Questions (FAQ)

Common questions about Metrosel (FAQ)

Q: How quickly does Metrosel usually start to have an effect?

A: Regulatory documents indicate that Metrosel is typically well-absorbed following administration. Studies show that the concentration in the bloodstream reaches its peak within one to two hours after taking the oral form. However, as with many antimicrobial treatments, official patient information advises completing the full prescribed course, as full efficacy may be achieved over the entire treatment duration.

Q: Is Metrosel the same as [Name of a similar common drug]?

A: Official information classifies Metrosel (Metronidazole) as a synthetic nitroimidazole derivative. This refers to a distinct chemical class of antimicrobial agents. Its mechanism of action targets specific anaerobic bacteria and protozoa, distinguishing it chemically from many other types of antibiotics.

Q: Can Metrosel affect how birth control pills work?

A: Official drug labeling notes that the effectiveness of some oral contraceptive products may be reduced when Metrosel is used concurrently. This potential interaction is a topic commonly discussed with a healthcare provider.

Q: What kind of research has been done on Metrosel for its current uses?

A: Official research summarized in regulatory documents has established Metrosel's strong activity against specific anaerobic bacteria and protozoal parasites. The body of research establishes the drug’s profile for its officially recognized uses.

Q: Does taking Metrosel require any special monitoring by a healthcare provider?

A: Yes. Regulatory documentation officially recommends monitoring of total and differential leukocyte (white blood cell) counts before and after therapy. This monitoring is especially noted in situations where a second course of treatment may be considered.

Q: Can Metrosel be crushed or split if the tablet is too large?

A: The official instructions for extended-release tablets state that they must be swallowed whole and are restricted from being chewed or crushed. Because specific restrictions can depend on the exact formulation, it is described as best to check the patient information leaflet for the particular form being used.

Q: How is Metrosel different from older treatments for the same condition?

A: Metrosel is formally defined as a synthetic nitroimidazole derivative. Its mechanism of action, which requires reductive bioactivation inside the target microbe, is a distinguishing factor of this class.

Q: What is the official public understanding of how Metrosel works?

A: Metrosel acts as an inactive substance, or prodrug, that is only activated inside the target microbe. Once activated by specialized enzymes found in anaerobic organisms, it forms highly reactive substances. These substances then damage the microbe's core DNA, which causes the cell to die.

Q: Is the effect of Metrosel immediate or does it build up over time?

A: While the drug is absorbed quickly, regulatory information advises patients to complete the full course of therapy, even if they begin to feel better early. This necessity is related to the goal of achieving the best clinical outcome and minimizing the risk of recurrence or developing drug resistance.

Q: What are the conditions where Metrosel is not recommended?

A: Use is officially contraindicated (prohibited) for patients with a known hypersensitivity to the drug, those who have recently used disulfiram, or those consuming alcohol. Caution is also officially advised for patients with severe liver impairment, certain Central Nervous System diseases, and those diagnosed with Cockayne Syndrome.

Q: What happens if Metrosel is stopped suddenly?

A: Official patient counseling states that skipping doses or not completing the full prescribed course of therapy may lead to the treatment being less effective. This can increase the likelihood of the infection coming back and may also contribute to the development of drug resistance.

Q: Is it normal to feel slightly nauseous when first starting Metrosel?

A: Nausea is listed in regulatory documents as one of the most frequently reported adverse effects. The official product information notes that taking the medication with food is a listed condition that may help minimize potential stomach discomfort.

Q: Can I drive or operate machinery while using Metrosel?

A: The drug label lists common nervous system effects, including dizziness and headache. Official warnings regarding the potential for dizziness and other central nervous system effects are relevant to activities requiring mental alertness, such as driving or operating machinery.

Q: Are there different strengths or forms of Metrosel available?

A: Yes. According to official labeling, Metrosel is available in oral tablets of 250 mg and 500 mg strengths. It is also supplied in multiple forms, including products for intravenous use, extended-release oral tablets, capsules, and specialized topical or vaginal applications.

Q: How do doctors generally determine who is eligible for Metrosel?

A: Official guidelines limit the use of Metrosel to treating infections that are caused by susceptible anaerobic bacteria and protozoal parasites. A healthcare provider must confirm or strongly suspect one of these specific types of infections before prescribing the medication.

Q: Is there a maximum time frame for how long someone can use Metrosel?

A: Official patient warnings state that a serious neurological safety concern, peripheral neuropathy, has been associated with prolonged duration of use or high doses. This highlights that the overall length of time the medication is taken is a key safety consideration defined by regulatory bodies.

Q: What should I do if I suspect an allergic reaction to Metrosel?

A: Official safety information documents the risk of severe hypersensitivity reactions, including anaphylaxis. Regulatory documents list severe hypersensitivity events, such as anaphylaxis, as conditions that necessitate emergency evaluation.

Q: Does Metrosel need to be taken at a specific time of day?

A: Official instructions define dosage based on fixed intervals, such as every 6 or 8 hours, or under certain conditions, such as once daily on an empty stomach. The requirement is focused on maintaining these fixed intervals rather than aligning with a specific clock time.

Q: Why is Metrosel sometimes described as having a unique mechanism of action?

A: The mechanism is considered unique because Metrosel is an inactive substance that requires a process called reductive bioactivation to work. This activation step occurs only inside the target anaerobic bacteria and protozoa, restricting the drug's effect primarily to the harmful microorganisms.

Q: Has Metrosel been studied in children or adolescents?

A: Yes. Official documentation confirms that the use of Metrosel in pediatric patients has been investigated. Specific dosing regimens are provided in the labeling for children for established uses, such such as treating amebiasis.

Q: Are there any known common skin reactions linked to Metrosel?

A: While severe skin reactions are rare, regulatory documents note that common skin reactions include conditions such as rash and pruritus (itching). The labeling describes the range of possible skin reactions, from common rashes to rare severe events.

Q: Is there a link between Metrosel and changes in mood?

A: The official list of documented adverse effects includes psychiatric disorders such as hallucinations, confusion, and depression. These are reported effects that may be linked to changes in mood.

Q: What is the official safety classification of Metrosel for breastfeeding mothers?

A: Official documentation confirms that Metrosel is transferred into breast milk. Regulatory guidance advises that a decision must be made whether to temporarily discontinue nursing or discontinue the drug, taking into account the drug's importance to the mother's health.

Q: Does Metrosel have any known interactions with heart medications?

A: The official product label includes a specific warning about potential interactions with certain medications that are known to affect heart rhythm, commonly referred to as QT prolonging drugs.

Q: Is Metrosel known to cause changes in appetite or weight?

A: Official reporting of adverse effects includes loss of appetite and weight loss as documented effects. These are typically listed under the general category of gastrointestinal or other reported systemic reactions.

Q: What is the primary excretion route for Metrosel (urine, feces, etc.)?

A: Regulatory documents indicate that Metrosel and its active metabolites are primarily eliminated from the body through the urine, accounting for the major route of excretion.

Q: Does official research cover the use of Metrosel in the elderly?

A: Yes. Official documentation includes studies and specific dosage considerations for the elderly population, generally defined as subjects over 70 years old. These studies noted that this population may have higher exposure to the active metabolite of the drug.

Q: What common misconceptions about Metrosel are clarified in official patient information?

A: Patient counseling information clarified by regulatory bodies focuses on the fact that Metrosel, as an antibacterial drug, is ineffective against viral infections like the common cold or flu. It should therefore only be used for the specific bacterial or protozoal infections for which it was prescribed.

How should Metrosel be stored and disposed of?

Storage and Disposal of Metrosel (Metronidazole)

Official regulatory documentation requires Metrosel to be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product must be protected from light and excessive humidity; oral forms are required to be kept in a well-closed, light-resistant container.

Handling Restriction Environmental Protection
Do not refrigerate or freeze. Keep out of the sight and reach of children.
Administer IV product promptly after unwrapping. Do not dispose of in wastewater or household rubbish.

Disposal must follow regulated procedures. Patients should consult a pharmacist or local waste authority for instructions on discarding unused or expired product, ensuring adherence to environmental protection guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Metrosel found in:

A-Z Index: